← Back to Clinical Trials
Recruiting NCT06802952

NCT06802952 RTMS for CHR Based on Personalized Targets Using Magnetoencephalography

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06802952
Status Recruiting
Phase
Sponsor Shanghai Mental Health Center
Condition Clinical High-risk Syndrome of Psychosis
Study Type INTERVENTIONAL
Enrollment 26 participants
Start Date 2025-02-07
Primary Completion 2026-12-31

Trial Parameters

Condition Clinical High-risk Syndrome of Psychosis
Sponsor Shanghai Mental Health Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 26
Sex ALL
Min Age 13 Years
Max Age 35 Years
Start Date 2025-02-07
Completion 2026-12-31
Interventions
rTMS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study is an before-after study in the same subject, which enrolled 26 individuals with high-risk psychiatric syndrome (CHR). The target of subjects intervention relies on the results of magnetoencephalography localization. The medication and dosage remain unchanged during the intervention period or not yet taking antipsychotic medication. The investigators assume that the intervention targets for each CHR subject are individualized.

Eligibility Criteria

Inclusion Criteria: * Clinical diagnosis of Clinical High-Risk Syndrome for Psychosis * Must be able to right-handed * Primary school education or above * Understand and sign a written informed consent form (jointly signed by the guardian and the participant if under 18 years old) Exclusion Criteria: * Major physical illnesses (organic lesions such as sensory and motor disorders, neurological disorders, and traumatic brain injury) * Taboo symptoms for rTMS treatment (such as intracranial metal implants) * Metal (including orthodontic treatment, dental implants) and tattoos inside the body * Claustrophobia

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology